Events - Invivoscribe

UPCOMING EVENTS

Invivoscribe to Exhibit at ASCO 2019

admin2019-07-11T05:21:26+00:00May 22nd, 2019|

CHICAGO, IL
Jun 01 – Jun 03, 2019

Invivoscribe to Present at The Inaugural World Pharma Week

admin2019-07-11T05:22:32+00:00May 22nd, 2019|

BOSTON, MA
Jun 17 - Jun 20, 2019

Invivoscribe to Exhibit at ASCO 2019

admin2019-07-11T05:21:26+00:00May 22nd, 2019|

CHICAGO, IL
Jun 01 – Jun 03, 2019

Invivoscribe to Present at The Inaugural World Pharma Week

admin2019-07-11T05:22:32+00:00May 22nd, 2019|

BOSTON, MA
Jun 17 - Jun 20, 2019

Invivoscribe to Exhibit at ASCO 2019

admin2019-07-11T05:21:26+00:00May 22nd, 2019|

CHICAGO, IL
Jun 01 – Jun 03, 2019

Invivoscribe to Present at The Inaugural World Pharma Week

admin2019-07-11T05:22:32+00:00May 22nd, 2019|

BOSTON, MA
Jun 17 - Jun 20, 2019

Invivoscribe to Exhibit at ASCO 2019

admin2019-07-11T05:21:26+00:00May 22nd, 2019|

CHICAGO, IL
Jun 01 – Jun 03, 2019

Invivoscribe to Present at The Inaugural World Pharma Week

admin2019-07-11T05:22:32+00:00May 22nd, 2019|

BOSTON, MA
Jun 17 - Jun 20, 2019

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate
drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

UPCOMING EVENTS

Invivoscribe to Exhibit at ASCO 2019

Invivoscribe to Present at The Inaugural World Pharma Week

PAST EVENTS

Invivoscribe to Exhibit at ASCO 2019

Invivoscribe to Present at The Inaugural World Pharma Week

UPCOMING EVENTS

Invivoscribe to Exhibit at ASCO 2019

Invivoscribe to Present at The Inaugural World Pharma Week

PAST EVENTS

Invivoscribe to Exhibit at ASCO 2019

Invivoscribe to Present at The Inaugural World Pharma Week

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019 Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018 A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018 Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

UPCOMING EVENTS

Invivoscribe to Exhibit at ASCO 2019

Invivoscribe to Present at The Inaugural World Pharma Week

PAST EVENTS

Invivoscribe to Exhibit at ASCO 2019

Invivoscribe to Present at The Inaugural World Pharma Week

UPCOMING EVENTS

Invivoscribe to Exhibit at ASCO 2019

Invivoscribe to Present at The Inaugural World Pharma Week

PAST EVENTS

Invivoscribe to Exhibit at ASCO 2019

Invivoscribe to Present at The Inaugural World Pharma Week

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL